Psychedelic Therapy and Depression: What the Research Shows

Psychedelic-assisted therapy is one of the most closely watched areas of depression research. Clinical trials pairing psychedelic substances with structured psychotherapy have reported encouraging results, particularly for treatment-resistant depression, and regulators have judged the evidence incomplete: Health Canada has not authorized any psychedelic as a treatment for depression, and larger trials are still underway. This article covers where the research stands, how trials work, and what the risks are.

Can you take psychedelics for depression?

Not legally in Canada, outside of narrow circumstances. Most psychedelics are controlled substances, and Health Canada has not authorized any of them as a treatment for depression or any other condition. The only lawful way to receive them is through a federally authorized clinical trial or other tightly controlled, practitioner-initiated pathways.

Within those research settings, psychedelics are almost never studied on their own. Trials pair the drug experience with structured psychotherapy before, during, and after the dosing session, and researchers believe the therapy component is central to any benefit.

What is psychedelic therapy for depression?

In depression trials, psychedelic-assisted therapy typically follows a four-step framework:

• Step 1: Screening and education. Researchers assess whether a participant is eligible, review their medical and psychiatric history, and explain the potential benefits and risks of taking part. Screening matters especially for depression, since people with certain conditions or on certain medications are excluded from trials.

• Step 2: Preparation. The participant attends one or more sessions with the study's therapists to prepare for the dosing session, set expectations, and build trust with the team who will be present.

• Step 3: The dosing session. The participant receives the drug in a controlled setting, with trained facilitators present for the entire session, which can last several hours.

• Step 4: Integration. In follow-up sessions, the participant works with a therapist to process and contextualize the experience. The experience can be confusing or distressing, and researchers consider this stage essential to any therapeutic effect.

Protocols vary between studies, and researchers are still working out which elements matter most.

Psychedelics carry real risks for people with depression, including difficult experiences during and after use. Anyone seeking help for depression can work with a licensed therapist using established, legal approaches with decades of evidence behind them.

How does psychedelic therapy work for depression?

Researchers are still working this out. In clinical trials, the integration stage is where participants work to draw insights from the experience, and researchers believe this stage is central to any therapeutic effect. The physical mechanisms are less understood, and to date there is no conclusive model explaining how psychedelics affect depression at the level of the brain.

The research is early but active. A systematic review and meta-analysis of 14 studies found short- and long-term symptom improvements found short- and long-term symptom improvements associated with several classic psychedelics paired with therapy, and a review of long-term effects looks at what is known about lasting changes from psychedelic use, an area where evidence remains thin. The usual caveats apply across this literature: small samples, difficulty blinding participants, and short follow-up periods, which is why no regulator has approved a psychedelic as a depression treatment.

What substances are being studied in psychedelic therapy for depression?

Researchers have studied several substances in combination with psychotherapy for depression, some far more thoroughly than others.

The most studied psychedelic-assisted therapy

The psychedelic most studied for depression is the active compound in what are commonly called "magic" mushrooms; trials use a synthetic, pharmaceutical-grade form in measured doses. Systematic reviews and meta-analyses report reductions in depressive symptoms among trial participants, including in reviews focused on major depressive disorder, while consistently noting the same limitations: small samples, blinding problems, and short follow-up. Larger trials are underway, and Health Canada has not approved it as a treatment for any condition.

Dissociative anaesthetic assisted treatment

There is one approved anaesthetic in Canada and the USA, and physicians can legally prescribe it off-label. Research on dissociative anaesthetic assisted treatment and depression is comparatively advanced. A randomized clinical trial found rapid reductions in suicidal thoughts compared with an active control, and a large trial in the New England Journal of Medicine found the dissociative anaesthetic performed comparably to electroconvulsive therapy for treatment-resistant depression. The durability of it's effects remains an open question, and a related medication has been approved in Canada for treatment-resistant depression, available only through a physician. Off-label use is a decision made by a physician with their patient.

Other Psychedelics

Evidence for other psychedelics and depression is thinner. The psychedelic most studied for PTSD has produced only a small number of reviews reporting short-term mood effects, and no trial has established it as a depression treatment. For substances widely studied in the 1950s and 1960s before research largely stopped, systematic reviews of classical psychedelics draw mostly on older or small studies, and some modern research examines acute effects on emotional processing rather than depression outcomes.

Microdosing

"Microdosing" refers to taking small, sub-hallucinogenic amounts of psychedelics on an ongoing basis. The evidence for depression is weak. Survey studies report that people who microdose describe lower levels of anxiety and depression than non-microdosers, but these are self-reports from people who chose to microdose, not controlled trials. Reviews of the field note that placebo-controlled studies have generally struggled to distinguish microdosing's effects from placebo.

What are the effects of psychedelic therapy for depression?

Effects vary widely depending on the substance, the dosage, the therapeutic framework, and the severity of symptoms. The time course varies too: dissociative anaesthetic assisted treatment studies have reported rapid reductions in some symptoms, including suicidal thinking, though these effects often fade within days or weeks and researchers are still studying how to sustain them. For microdosing, controlled studies have generally failed to show a benefit for depression at all.

Psychedelic experiences are also highly subjective. One trial participant may describe a profound mental or spiritual epiphany, while another, at the same dose, may find the experience frightening or destabilizing. For people with depression, difficult experiences carry particular weight, which is why trial protocols keep trained facilitators present throughout the dosing session and treat integration as essential. In follow-up sessions, participants work with therapists to make sense of what happened, whether the experience was positive or difficult.

Psychedelics and antidepressants

Few studies have examined the risks of combining psychedelics with antidepressants, and the risks differ by substance. In clinical trials, participants taking SSRIs are typically tapered off under medical supervision before receiving the study drug, for two reasons:

• Serotonin syndrome. Certain psychedelics, particularly those with stimulant properties or those containing MAO inhibitors, can interact with SSRIs and cause serotonin syndrome, a serious and potentially fatal condition.‍
• Blunted effects. Some antidepressants appear to reduce the effects of some psychedelics, which complicates research and means the interactions are not fully understood.

Other psychedelics are not typically associated with serotonin syndrome, though data on their interactions with antidepressants remains limited. Because the risk profile depends on the specific substance, this is a conversation for a physician, never guesswork.

Key takeaways:

• Psychedelics are controlled substances in Canada, and none have been authorized by Health Canada as a treatment for depression or any other condition. The only lawful access is through clinical trials and other narrow, federally controlled pathways.
• The most studied psychedelic-assisted therapy for depression has shown promising results in trials that are small and hard to blind, and regulators consider the evidence incomplete while larger studies run.
• There is an approaved dissociative anaesthetic that physicians can prescribe off-label, a decision made between a doctor and their patient.
• Trials pair the drug with structured preparation and integration therapy, and researchers believe the therapy component is central to any benefit.
• Anyone seeking help for depression can work with a licensed therapist using established, legal approaches with decades of evidence behind them.